All In Biotech

Drug Trial Radar · NCT02138916

Benralizumab Efficacy in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History

Randomised, Double-blind, 56 Week Placebo-controlled, Parallel Group, Multicentre, Phase 3 Study to Evaluate the Efficacy and Safety of 2 Doses of Benralizumab in Patients With Moderate to Very Severe COPD With a History of Exacerbations

Last checked: Nov 20, 2026Latest source record: Jun 13, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,656 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,656

Actual

Start

Jun 13, 2014

Primary completion

Apr 10, 2018

Study completion Apr 10, 2018

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
Collaborators
MedImmune LLC
First posted
May 15, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 40 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to determine if benralizumab reduces COPD exacerbation rate in symptomatic patients with moderate to very severe COPD who are receiving standard of care therapies

Conditions

  • Moderate to Very Severe Chronic Obstructive Pulmonary Disease

Interventions

  • Benralizumab Arm ADrug

    Benralizumab subcutaneously on study week 0 until study week 48 inclusive

  • Benralizumab Arm BDrug

    Benralizumab subcutaneously on study week 0 until study week 48 inclusive

  • PlaceboDrug

    Placebo subcutaneously on study week 0 until study week 48 inclusive

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Annual COPD Exacerbation Rate Over 56 Weeks Treatment Comparison for Patients With Baseline EOS>=220/uLTime frame: From first IP to week 56

Locations

407 sites in 17 countries. Site status is shown where the registry gives one.

  • Research Site

    Andalusia, Alabama

  • Research Site

    Birmingham, Alabama

  • Research Site

    Birmingham, Alabama

  • Research Site

    Dothan, Alabama

  • Research Site

    Jasper, Alabama

  • Research Site

    Little Rock, Arkansas

  • Research Site

    Beverly Hills, California

  • Research Site

    Gold River, California

  • Research Site

    Huntington Beach, California

  • Research Site

    Huntington Park, California

  • Research Site

    Lakewood, California

  • Research Site

    Lomita, California

  • Research Site

    Newport Beach, California

  • Research Site

    Palm Desert, California

  • Research Site

    Palo Alto, California

  • Research Site

    Riverside, California

  • Research Site

    Sacramento, California

  • Research Site

    San Diego, California

  • Research Site

    Santa Ana, California

  • Research Site

    Thousand Oaks, California

  • Research Site

    Torrance, California

  • Research Site

    New Haven, Connecticut

  • Research Site

    Waterbury, Connecticut

  • Research Site

    Boynton Beach, Florida

  • Research Site

    Brandon, Florida

  • Research Site

    Clearwater, Florida

  • Research Site

    Clearwater, Florida

  • Research Site

    Fort Lauderdale, Florida

  • Research Site

    Gainesville, Florida

  • Research Site

    Hialeah, Florida

  • Research Site

    Kissimmee, Florida

  • Research Site

    Loxahatchee Groves, Florida

  • Research Site

    Miami, Florida

  • Research Site

    Miami, Florida

  • Research Site

    Miami, Florida

  • Research Site

    Miami, Florida

  • Research Site

    Miami Springs, Florida

  • Research Site

    Orlando, Florida

  • Research Site

    Orlando, Florida

  • Research Site

    Orlando, Florida

Showing 40 of 407 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.